Catalyst Pharmaceuticals Partners

Catalyst is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs

Catalyst is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms and Tourette's disorder. Catalyst is developing Firdapse (Amifampridine Phosphate, or 3,4-diaminopyridine phosphate) for the treatment of LEMS, a rare neuromuscular, autoimmune disorder frequently associated with small cell lung cancer. Catalyst also believes that Firdapse has the potential to treat other neuromuscular disorders such as congenital myasthenic syndrome and some cases of myasthenia gravis that are refractory to currently approved therapies.